Novartis AG NVS
Set alert
At close · Oct 30
After hours · Oct 30, 4:22 PM ET
- YTD
- +16.62%
- 1 year
- +31.14%
- Open
- 162.53
- Prev close
- 161.10
- Mkt cap
- 303.67B
- Vol
- 3.15M
- Avg vol
- 2.02M
- EPS
- 5.24
- P/E
- 30.69
- Div yield
- 2.94%
More statistics
- Low
- 160.42
- High
- 164.06
- Forward P/E
- 16.23
- Beta
- 0.47
- Short ratio
- 3.01
- Inst. own
- 7.31%
- Dividend
- 4.74
- Ex-div date
- Mar 10, 2026
- Earnings
- Feb 3, 2027
- 50-d avg
- 148.31
- 200-d avg
- 151.74
- 1y target
- 155.29
5Y chart
Events in this range
- Mar 8, 2022Dividend: 3.32525
- Mar 9, 2023Dividend: 3.4987
- Mar 7, 2024Dividend: 3.19863
- Sep 24, 2024Dividend: 3.77721
- Mar 12, 2025Dividend: 3.99399
- Sep 12, 2025Downgrade: Goldman Sachs · Neutral → Sell
- Oct 28, 2025Earnings: 2.25; estimate 2.26; surprise -0.44%
- Dec 8, 2025Rating: JP Morgan · Neutral → Overweight
- Jan 6, 2026Rating: Barclays · Underweight → Equal-Weight
- Feb 4, 2026Earnings: 2.03; estimate 1.99; surprise 2.01%
- Mar 11, 2026Dividend: 4.74025
- Mar 26, 2026Rating: Morgan Stanley · Overweight → Overweight
- Apr 28, 2026Earnings: 1.99; estimate 2.11; surprise -5.69%
- Jul 21, 2026Earnings: 2.41; estimate 2.17; surprise 11.06%
- Sep 10, 2026Rating: HSBC · Reduce → Hold
- Oct 27, 2026Earnings: 2.46; estimate 2.25; surprise 9.33%
- Oct 30, 2026Downgrade: Deutsche Bank · Hold → Sell
Signals (92)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 26, 2026 | 6 days ago |
| SMA: Bullish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| RSI: Overbought | Jan 19, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 17, 2025 | 11 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | May 19, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bullish | Apr 7, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Feb 17, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 10, 2025 | 1 year ago |
| SMA: Bullish | Jan 27, 2025 | 1 year ago |
| SMA: Bearish | Nov 4, 2024 | 1 year ago |
| SMA: Bearish | Oct 21, 2024 | 2 years ago |
| SMA: Bullish | Oct 7, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 7, 2024 | 2 years ago |
| SMA: Bearish | Sep 30, 2024 | 2 years ago |
| RSI: Overbought | Aug 19, 2024 | 2 years ago |
| MACD: Buy Signal | May 13, 2024 | 2 years ago |
| SMA: Bullish | May 6, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 4, 2024 | 2 years ago |
| SMA: Bearish | Feb 26, 2024 | 2 years ago |
| SMA: Bullish | Feb 19, 2024 | 2 years ago |
| SMA: Bearish | Feb 5, 2024 | 2 years ago |
| SMA: Bullish | Dec 25, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 25, 2023 | 2 years ago |
| SMA: Bullish | Nov 20, 2023 | 2 years ago |
| SMA: Bearish | Oct 2, 2023 | 3 years ago |
| SMA: Bearish | Oct 2, 2023 | 3 years ago |
| SMA: Bullish | Sep 25, 2023 | 3 years ago |
| SMA: Bearish | Sep 18, 2023 | 3 years ago |
| SMA: Bullish | Sep 11, 2023 | 3 years ago |
| SMA: Bearish | Aug 28, 2023 | 3 years ago |
| SMA: Bullish | Aug 21, 2023 | 3 years ago |
| SMA: Bearish | Aug 14, 2023 | 3 years ago |
| SMA: Bullish | Jul 17, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 3, 2023 | 3 years ago |
| SMA: Bearish | Jun 19, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| SMA: Bearish | May 22, 2023 | 3 years ago |
| RSI: Overbought | Apr 17, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 3, 2023 | 3 years ago |
| SMA: Bullish | Mar 27, 2023 | 3 years ago |
| SMA: Bullish | Mar 27, 2023 | 3 years ago |
| SMA: Bearish | Feb 27, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 6, 2023 | 3 years ago |
| SMA: Bearish | Jan 23, 2023 | 3 years ago |
| SMA: Bullish | Nov 7, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 7, 2022 | 3 years ago |
| SMA: Bullish | Oct 24, 2022 | 4 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| SMA: Bullish | Jul 25, 2022 | 4 years ago |
| SMA: Bearish | Jun 6, 2022 | 4 years ago |
| SMA: Bearish | May 30, 2022 | 4 years ago |
| SMA: Bullish | May 16, 2022 | 4 years ago |
| SMA: Bearish | May 2, 2022 | 4 years ago |
| SMA: Bullish | Mar 14, 2022 | 4 years ago |
| SMA: Bearish | Feb 28, 2022 | 4 years ago |
| SMA: Bullish | Feb 21, 2022 | 4 years ago |
| SMA: Bearish | Feb 7, 2022 | 4 years ago |
Key statistics
- Market cap
- 303.71B
- Enterprise value
- 344.03B
- Trailing P/E
- 30.69
- Forward P/E
- 16.23
- PEG ratio
- 3.85
- Price / sales
- 5.29
- Price / book
- 8.16
- EPS (TTM)
- 5.24
- Beta
- 0.47
- Dividend yield
- 2.94%
- Payout ratio
- 90.46%
- Profit margin
- 17.49%
- Revenue (TTM)
- 57.36B
- Revenue growth
- 4.70%
- Free cash flow
- 11.27B
- Total cash
- 8.87B
- Total debt
- 48.31B
- Return on equity
- 24.33%
- Shares outstanding
- 1.89B
- Short % of float
- 0.30%
- 50-day average
- 148.31
- 200-day average
- 151.74
Analyst view
Consensus: hold
- Target (low)
- 130.00
- Target (mean)
- 155.29
- Target (high)
- 185.00
- Strong buy3
- Buy2
- Hold5
- Sell1
- Strong sell1
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 2.23.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 2.23 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | 2.25 | 2.46 | +0.21 | +9.33% |
| Jul 21, 2026 | Jun 30, 2026 | 2.17 | 2.41 | +0.24 | +11.06% |
| Apr 28, 2026 | Mar 31, 2026 | 2.11 | 1.99 | -0.12 | -5.69% |
| Feb 4, 2026 | Dec 31, 2025 | 1.99 | 2.03 | +0.04 | +2.01% |
| Oct 28, 2025 | Sep 29, 2025 | 2.26 | 2.25 | -0.01 | -0.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Deutsche Bank | down | Hold | Sell |
| Sep 10, 2026 | HSBC | up | Reduce | Hold |
| Mar 26, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Jan 6, 2026 | Barclays | up | Underweight | Equal-Weight |
| Dec 8, 2025 | JP Morgan | up | Neutral | Overweight |
| Sep 12, 2025 | Goldman Sachs | down | Neutral | Sell |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Switzerland
- Website
- novartis.com
News
- Companies promised AI gains— here's how the payoff showed up in earnings
- Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach
- All You Need to Know About Novartis (NVS) Rating Upgrade to Buy
- Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
- A pharma giant is moving past one patent cliff — but another is already looming
- Novartis AG (NVS) Q3 2026 Earnings Call Transcript
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In Psoriatic Arthritis
- Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In People Living With Active Moderate To Severe Psoriatic Arthritis
- What Novartis (NVS) Said on Its Q3 Earnings Call
Your note
Sign in to keep a note on NVS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fisher Asset Management, LLC | 0.76% | 15,523,378 | 2.50B | Jun 29, 2026 |
| Morgan Stanley | 0.43% | 8,726,827 | 1.40B | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 0.40% | 8,117,586 | 1.31B | Jun 29, 2026 |
| Primecap Management Company | 0.32% | 6,592,124 | 1.06B | Jun 29, 2026 |
| LOOMIS SAYLES & CO L P | 0.26% | 5,239,309 | 842.53M | Jun 29, 2026 |
| Bank of America Corporation | 0.24% | 4,909,938 | 789.57M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 0.21% | 4,252,875 | 683.90M | Jun 29, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT. | 0.10% | 2,060,639 | 331.37M | Jul 30, 2026 |
| LOOMIS SAYLES FUNDS II-Loomis Sayles Growth Fund | 0.07% | 1,417,894 | 228.01M | Jun 29, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund | 0.06% | 1,211,220 | 194.78M | Jun 29, 2026 |
| Franklin Mutual Series Funds-FRANKLIN MUTUAL GLOBAL DISCOVERY FUND | 0.06% | 1,192,174 | 191.71M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 0.05% | 949,726 | 152.73M | Jun 29, 2026 |